Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers - 27/10/20
pagine | 17 |
Iconografia | 5 |
Video | 0 |
Altro | 0 |
Graphical Abstract |
Highlights |
• | Ferroptosis attract increasingly attention with a process involving many factors. |
• | Negative regulator of ferroptosis such as GPX4, NRF2 can promote cancer resistance. |
• | High metastasis and resistant cancer are vulnerable to ferroptosis inducer treatment. |
• | Synthetic compounds and clinical drugs can used for resistant cancer by ferroptosis. |
• | The combination of nanoparticle induced ferroptosis can be used for resistant cancer. |
Abstract |
The development of chemotherapy drugs has promoted anticancer treatment, but the effect on tumours is not clear because of treatment resistance; thus, it is necessary to further understand the mechanism of cell death to explore new therapeutic targets. As a new type of programmed cell death, ferroptosis is increasingly being targeted in the treatment of many cancers with clinical drugs and experimental compounds. Ferroptosis is stimulated in tumours with inherently high levels of ferrous ions by a reaction with abundant polyunsaturated fatty acids and the inhibition of antioxidant enzymes, which can overcome treatment resistance in cancers mainly through GPX4. In this review, we focus on the intrinsic cellular regulators against ferroptosis in cancer resistance, such as GPX4, NRF2 and the thioredoxin system. We summarize the application of novel compounds and drugs to circumvent treatment resistance. We also introduce the application of nanoparticles for the treatment of resistant cancers. In conclusion, targeting ferroptosis represents a considerable strategy for resistant cancer treatment.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Ferroptosis, Cancer resistance, Antioxidant, Drug therapy, Nanoparticles
Mappa
Vol 130
Articolo 110710- Ottobre 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?